Navigation Links
Stereotaxis Reports Fourth Quarter 2008 Financial Results

ST. LOUIS, Feb. 26 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today reported its financial results for the fourth quarter ended December 31, 2008. Revenue for the fourth quarter of 2008 was $12.1 million, an increase of 18% over the fourth quarter of 2007. Stereotaxis recognized revenue on seven Niobe(R) Magnetic Navigation Systems and four Odyssey(TM) systems in the quarter. Revenue from sales of the Niobe and Odyssey systems totaled $8.7 million. Recurring revenue from disposables, services and accessories was $3.4 million. New orders in the fourth quarter for both Niobe and Odyssey systems were $11 million and backlog at December 31, 2008 totaled $69 million. The Company continued to drive cost efficiencies and lowered operating expenses to $14.6 million, which represented a 23% decline from the prior year's fourth quarter and a 9.5% decline from the third quarter of 2008.

Michael P. Kaminski, President and Chief Executive Officer, commented, "Our fourth quarter results were in line with our preliminary announcement and reflected some very positive trends, including the increase in revenue, continued strength of gross margins and lower operating expenses. As a result, our operating loss declined by 48% compared to the fourth quarter of last year as we continuously move Stereotaxis toward breakeven."

"The roll-out of the Thermocool irrigated catheter in Europe is proceeding well and the results have been very encouraging," continued Mr. Kaminski. "The Thermocool catheter is currently in use at 29 sites in Europe and since its reintroduction in September, utilization in Europe has increased significantly. The procedures performed to date to treat complex arrhythmias have confirmed that the efficacy, efficiency and safety record of the irrigated catheter is unsurpassed in the industry and we believe its performance has the potential to set a new standard for EP labs. As we look to the year ahead, once the magnetic irrigated catheter is approved by the U.S. Food and Drug Administration, our goal is to generate market interest in the Niobe system and resulting order momentum matching what we have achieved in Europe."

"Cash and cash equivalents totaled $30 million at the end of the year. Included in this total was $19 million in net proceeds from the additional equity that we raised in December 2008. We believe increased acceptance of our Niobe platform and Odyssey, along with our reduced expense structure and our balance sheet strength and flexibility, will position Stereotaxis to grow revenue and achieve much improved bottom-line results in 2009," concluded Mr. Kaminski.

Fourth Quarter and Full Year 2008 Financial Performance

Gross margin for the quarter was $8.2 million, or 68% of revenue, compared with $6.5 million, or 64% of revenue in the fourth quarter of 2007. Fourth quarter operating expenses decreased 23% to $14.6 million, compared to $18.9 million in the fourth quarter of 2007.

The Company reported a net loss for the fourth quarter of 2008 of $7.5 million, or $(0.20) per share. This compares to a net loss of $12.2 million, or $(0.34) per share, in the fourth quarter of 2007. The weighted average shares for the recent fourth quarter were 36.7 million compared with 36.3 million in the fourth quarter of last year.

For the full year 2008, revenue totaled $40.4 million compared with revenue of $39.3 million for 2007. The Company reported a net loss of $43.9 million for 2008 compared with a net loss of $48.1 million for 2007. On a per share basis, the net loss in 2008 represented $(1.20) compared with $(1.34) in 2007.

Cash used in operations was $3.4 million for the fourth quarter of 2008, and cash and investments at December 31, 2008 totaled $30.4 million, compared to $23.7 million at December 31, 2007.

Conference Call Information

The Company has scheduled a conference call for 8:30 a.m. Eastern Standard Time today to discuss its financial results for the fourth quarter. To access the conference call, please dial (800) 240-2134. International participants can call (303) 275-2170. An audio replay of the call will be available for seven days following the call at (800) 405-2236 for U.S. callers or (303) 590- 3000 for those calling outside the U.S. The password required to access the replay is 11125670#. The call will also be available on the Internet live and for 90 days thereafter at the following URL:

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

                              STEREOTAXIS, INC.
                           STATEMENTS OF OPERATIONS

                           Three Months Ended         Twelve Months Ended
                              December 31,                December 31,
                            2008          2007          2008          2007

       System            $8,743,693    $7,638,750   $28,375,880   $30,118,627
        service and
        accessories       3,382,791     2,616,113    11,989,293     9,180,182
    Total revenue        12,126,484    10,254,863    40,365,173    39,298,809

    Cost of revenue
       System             3,233,985     2,954,061    12,008,090    10,978,108
        service and
        accessories         693,558       764,897     2,169,700     2,497,459
        impairment                -             -             -     1,870,653
    Total cost of
     revenue              3,927,543     3,718,958    14,177,790    15,346,220

    Gross margin          8,198,941     6,535,905    26,187,383    23,952,589
    Operating expenses:
       Research and
        development       3,561,488     5,996,138    17,422,828    25,471,809
       Sales and
        marketing         5,363,663     8,287,708    28,660,663    29,021,117
       General and
        administration    5,663,051     4,589,694    21,121,164    18,701,726
    Total operating
     expenses            14,588,202    18,873,540    67,204,655    73,194,652
    Operating loss       (6,389,261)  (12,337,635)  (41,017,272)  (49,242,063)
    Interest income          29,205       258,859       194,870     1,471,503
    Interest expense     (1,131,965)     (134,455)   (3,063,572)     (350,954)
    Net loss            $(7,492,021) $(12,213,231) $(43,885,974) $(48,121,514)

    Net loss per common
       Basic and diluted     $(0.20)       $(0.34)       $(1.20)       $(1.34)

    Weighted average
     shares used in
     computing net loss
     per common share:
        Basic and
         diluted         36,714,618    36,331,376    36,585,086    35,793,973

                              STEREOTAXIS, INC.
                                BALANCE SHEETS

                                               December 31,      December 31,
                                                   2008              2007
    Current Assets:
       Cash and cash equivalents               $30,355,657       $17,022,200
       Short-term investments                                      6,634,178
       Accounts receivable, net of
        allowance of $328,307 and
        $189,040 in 2008                         9,739,008        13,757,270
          and 2007, respectively
       Current portion of long-term
        receivables                                197,351           136,430
       Inventories                               8,086,956         9,964,460
       Prepaid expenses and other current
        assets                                   2,966,510         3,421,202
    Total current assets                        51,345,482        50,935,740
    Property and equipment, net                  6,420,600         7,011,763
    Intangible assets                            1,277,778         1,411,111
    Long-term Receivables                          298,123           272,859
    Other assets                                    98,382           844,321
    Total assets                               $59,440,365       $60,475,794

    Liabilities and stockholders' equity
    Current liabilities:
       Current maturities of long-term
        debt                                      $666,667          $972,222
       Accounts payable                          4,561,928         7,349,426
       Accrued liabilities                       9,873,818        11,913,418
       Deferred contract revenue                 9,676,339         8,774,958
    Total current liabilities                   24,778,752        29,010,024

    Long term debt, less current maturities     28,506,371         6,000,000
    Long term deferred contract revenue          1,225,656           942,573
    Other liabilities                              158,905           328,790

    Stockholders' equity:
       Preferred stock, par value $0.001;
        10,000,000 shares authorized at
        2008 and 2007; none outstanding
        at 2008 and 2007                                 -                 -
       Common stock, par value $0.001;
        100,000,000 shares authorized at
        2008 and 2007; 42,049,792
        and 37,132,529 issued at 2008 and
        2007, respectively                          42,050            37,133
       Additional paid-in capital              300,892,957       276,433,662
       Treasury stock, 40,151 shares at
        2008 and 2007                             (205,999)         (205,999)
       Accumulated deficit                    (295,958,327)     (252,072,353)
       Accumulated other comprehensive
        gain                                             -             1,964
    Total stockholders' equity                   4,770,681        24,194,407
    Total liabilities and stockholders'
     equity                                    $59,440,365       $60,475,794

    Note:  Long-term debt includes $13,235,000 of working capital facility
           which is assumed to be extended through March 31, 2010.

SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Annouces First CTO Crossing Procedure With RF PowerAssert(TM) Magnetic Guidewire
2. Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants
3. Stereotaxis Reports Third Quarter 2008 Financial Results
4. Stereotaxis Announces New Management Appointment
5. Stereotaxis Reports Record Second Quarter Revenue
6. Stereotaxis Announces Second Quarter 2008 Earnings Release Date and Conference Call
7. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
8. Stereotaxis Reports Record First Quarter Orders
9. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
10. Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases
11. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
Post Your Comments:
(Date:11/29/2015)... , ... November 29, 2015 , ... Khanna Vision Institute ... Board of Ophthalmology on November 25th 2015. Peer Certification by the Board is ... his specialty. Certification in Ophthalmology is first obtained after the completion of three years ...
(Date:11/29/2015)... IL (PRWEB) , ... November 29, 2015 , ... Effective ... In addition starting on Black Friday Target is offering a “Buy One ... This is a rare opportunity to purchase IguanaMed at a discounted price. ...
(Date:11/28/2015)... ... November 28, 2015 , ... Trying to relax on ... the COUCH BUDDY. "I conceived of this design due to personal experience with a ... users. It promotes relaxation and convenience, as well as increases support. It also makes ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved ... can help protect a patient’s overall health. The talk stressed the link between periodontal ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Advanced Wound Care Market by Type (Dressings, ... End User (In-Patient Facility, Out-Patient Facility), and Geography - ... --> --> ... description, definition and forecast of the global advanced wound ...
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
Breaking Medicine Technology: